Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas.

Blood - 15 Jan 1997

Wilson W H, Teruya-Feldstein J, Fest T, Harris C, Steinberg S M, Jaffe E S, Raffeld M

Abstract excerpt

Although the cause(s) of clinical drug resistance in non-Hodgkin's lymphomas (NHL) is unknown, in vitro studies suggest that abnormalities of the p53 gene, bcl-2 overexpression, and low tumor proliferation rates may increase chemotherapy resistance. We analyzed tumor tissue from 75 patients with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Division
Share to Drug Resistance, Neoplasm
Share to Gene Expression Regulation, Neoplastic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lymphoma, Non-Hodgkin

Share to Mutation

Share to Proto-Oncogene Proteins c-bcl-2

Share to Tumor Suppressor Protein p53

Source

Identifiers

PMID: 9002964

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-9002964-2026-09-02.1. Manifest publication-graph-cohort-2026-09-02.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas.PMID 9002964Read ↗

Drug Resistance in Non-Hodgkin LymphomasSemantic proximity Read ↗

Predicting chemoresistance in human malignant glioma cells: the role of molecular genetic analyses.Semantic proximity Read ↗

Reversing Drug Resistance In VivoSemantic proximity Read ↗

Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: relationship between p53 gene mutation and bcl-2/bax proteins in drug resistance.Semantic proximity Read ↗

Drug Resistance to Inhibitors of the Human Double Minute-2 E3 Ligase Is Mediated by Point Mutations of p53, but Can Be Overcome with the p53 Targeting Agent RITASemantic proximity Read ↗

Correlations between intrinsic chemoresistance and HER-2/neu gene expression, p53 gene mutations, and cell proliferation characteristics in non-small cell lung cancer cell lines.Semantic proximity Read ↗

Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome.Semantic proximity Read ↗

Normal p53 status and function despite the development of drug resistance in human breast cancer cells.Semantic proximity Read ↗

P53, MDM-2, BAX and BCL-2 and Drug Resistance in Chronic Lymphocytic LeukemiaSemantic proximity Read ↗

Expression of p53 predicts treatment failure in aggressive non-Hodgkin's lymphomas.Semantic proximity Read ↗

Molecular mode of action and role of TP53 in the sensitivity to the novel epothilone sagopilone (ZK-EPO) in A549 non-small cell lung cancer cells.Semantic proximity Read ↗

p53 Mutations, c-myc and bcl-2 Rearrangements in Human Non-Hodgkin's Lymphoma Cell LinesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.